In this regard, Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors have emerged as a significant advancement in the treatment landscape of T2DM, with implications for CVD management [11,12]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.